JNJ's Jansen Biotech enters deal to collaborate on Imetelstat.

One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.

Imetelstat, a key blood cancer drug, is taken off FDA hold and can proceed to trial.

Recent FDA partial removal for the Phase 2 (Myelofibrosis IST) in June 2014 improved the fundamentals for Geron lead drug, Imetelstat.

The highest scoring names in small cap from 1 year ago (3/20/2013) returned 3,708 bps more than the S&P 500. The best performers have been RAD up 255%, CAMP up 205%, JAZZ up 163%, MDSO up 127%, GBX up 109%, and HOMB up 90%.